The primary objective of this Core will be to formulate cyanovirin (CV-N) into gel- and cream-based vaginal delivery systems. Since little is known regarding the physical function of vaginal dosage forms, the Core will support the proposed study of deployment by initially developing and supplying placebo formulations. These physical assessments of formulations and deployment will allow formulation development to proceed while recombinant CV-N production is being developed. Gel and cream formulations with a range of physical properties will be prepared and evaluated for spreading and coating properties in vitro, and for vaginal coating in vivo. These evaluations will provide feedback information for formulation optimization. CV-N will then be incorporated into optimized gel and cream formulations and tested in vitro for stability and drug release using standard pharmaceutical methods, and for biological activity. This evaluation will allow for advanced formulation optimization regarding biological activity. A variety of antimicrobial agents (e.g., C31G, defensins) and additional antiviral agents (e.g., UC781) will be incorporated into optimized CV-N gels and creams and evaluated using the same iterative optimization processes, leading to the availability of formulated combinations of microbicides. Analytical methods of determining CV-N (and other compounds) levels in formulations and in biological fluids will be developed as needed. Lastly, the Core will be responsible distributing CV-N (neat and formulated) to the other projects and cores.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI051650-01
Application #
6488612
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2002-04-01
Project End
2007-03-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Biosyn, Inc.
Department
Type
DUNS #
City
Huntingdon Valley
State
PA
Country
United States
Zip Code
19006
Su, H Irene; Schreiber, Courtney A; Fay, Courtney et al. (2011) Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides. Contraception 84:525-32
Barnhart, Kurt; Kulp, Jennifer L; Rosen, Mark et al. (2009) A randomized trial to determine the distribution of four topical gel formulations in the human vagina. Contraception 79:297-303
Owen, Derek H; Peters, Jennifer J; Kieweg, Sarah L et al. (2007) Biophysical analysis of prototype microbicidal gels. J Pharm Sci 96:661-9
McFadden, Karyn; Cocklin, Simon; Gopi, Hosahudya et al. (2007) A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins 67:617-29
Tien, Deborah; Schnaare, Roger L; Kang, Feirong et al. (2005) In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21:845-53
Colleluori, Diana M; Tien, Deborah; Kang, Feirong et al. (2005) Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein Expr Purif 39:229-36